AACR centennial series: the biology of cancer metastasis: historical perspective - PubMed (original) (raw)
Review
AACR centennial series: the biology of cancer metastasis: historical perspective
James E Talmadge et al. Cancer Res. 2010.
Abstract
Metastasis resistant to therapy is the major cause of death from cancer. Despite almost 200 years of study, the process of tumor metastasis remains controversial. Stephen Paget initially identified the role of host-tumor interactions on the basis of a review of autopsy records. His "seed and soil" hypothesis was substantiated a century later with experimental studies, and numerous reports have confirmed these seminal observations. An improved understanding of the metastatic process and the attributes of the cells selected by this process is critical for the treatment of patients with systemic disease. In many patients, metastasis has occurred by the time of diagnosis, so metastasis prevention may not be relevant. Treating systemic disease and identifying patients with early disease should be our goal. Revitalized research in the past three decades has focused on new discoveries in the biology of metastasis. Even though our understanding of molecular events that regulate metastasis has improved, the contributions and timing of molecular lesion(s) involved in metastasis pathogenesis remain unclear. Review of the history of pioneering observations and discussion of current controversies should increase understanding of the complex and multifactorial interactions between the host and selected tumor cells that contribute to fatal metastasis and should lead to the design of successful therapy.
(c)2010 AACR.
Figures
Figure 1
The process of cancer metastasis consists of sequential, interlinked, and selective steps with some stochastic elements. The outcome of each step is influenced by the interaction of metastatic cellular subpopulations with homeostatic factors. Each step of the metastatic cascade is potentially rate limiting such that failure of a tumor cell to complete any step effectively impedes that portion of the process. Therefore, the formation of clinically relevant metastases represents the survival and growth of selected subpopulations of cells that preexist in primary tumors.
Figure 2
Tumors can secrete growth factors and cytokines that result in the expansion and mobilization of myeloid progenitors from the marrow with trafficking to various extramedullary sites including the spleen, liver, lungs and primary and metastatic tumor lesions. These committed myeloid progenitors (CMP) can mature into dendritic cells (DCs) myeloid derived suppressor cells (MDSCs) and macrophages including tumor-associated macrophages (TAMs) as well as become activated, or “paralyzed”, within the tumor environment. These heterogeneous cells include progenitor cells, immature cells, mature, and activated cells. Dependent upon the infiltrating subset and extent of maturation and activation, these cells can be a critical component and regulator of angiogenesis, vascularogenesis, and tumor regression or growth.
Figure 3
The clonal selection model of metastasis suggests that the cell populations in the primary tumor with all of the genetic prerequisites required for metastatic capacity are the subpopulations that metastasize. Further, both the cells within the primary tumor and the metastatic lesion(s) can continue to diversify as the lesions grow.
Figure 4
The immune cells infiltrating tumors can regulate their growth, progression, and metastasis. Tumor regression is associated with infiltration by mature dendritic cells (DCs) and cytotoxic T cells (CTL) and type 1 T-helper type 1 bioactivity. Contrasting with this, tumor growth is facilitated via immune mediated immunosuppression and neoangiogenesis following infiltration of tumors with immature DCs, myeloid-derived suppressor cells, (MDSCs) plasmacytoid DCs, (pDCs) M2 macrophages, as well as T regulatory (T-reg) cells and a low frequency of CD4 and CD8 effector T cells.
Similar articles
- Stephen Paget and the 'seed and soil' theory of metastatic dissemination.
Ribatti D, Mangialardi G, Vacca A. Ribatti D, et al. Clin Exp Med. 2006 Dec;6(4):145-9. doi: 10.1007/s10238-006-0117-4. Clin Exp Med. 2006. PMID: 17191105 - Behavior of seeds and soil in the mechanism of metastasis: a deeper understanding.
Mathot L, Stenninger J. Mathot L, et al. Cancer Sci. 2012 Apr;103(4):626-31. doi: 10.1111/j.1349-7006.2011.02195.x. Epub 2012 Jan 29. Cancer Sci. 2012. PMID: 22212856 Free PMC article. Review. - Revisiting the seed and soil in cancer metastasis.
Mendoza M, Khanna C. Mendoza M, et al. Int J Biochem Cell Biol. 2009 Jul;41(7):1452-62. doi: 10.1016/j.biocel.2009.01.015. Epub 2009 Feb 3. Int J Biochem Cell Biol. 2009. PMID: 19401145 Free PMC article. Review. - Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Gonzalez-Angulo AM, et al. Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review. - The biology of cancer metastasis or, 'you cannot fix it if you do not know how it works'.
Fidler IJ. Fidler IJ. Bioessays. 1991 Oct;13(10):551-4. doi: 10.1002/bies.950131010. Bioessays. 1991. PMID: 1755831 Review.
Cited by
- Mapping the transcriptional evolution of human metastatic breast cancer.
Reeves MQ. Reeves MQ. J Clin Invest. 2024 Sep 3;134(17):e183971. doi: 10.1172/JCI183971. J Clin Invest. 2024. PMID: 39225091 Free PMC article. - Role of MicroRNA-204 in Regulating the Hallmarks of Breast Cancer: An Update.
Bermúdez M, Martínez-Barajas MG, Bueno-Urquiza LJ, López-Gutiérrez JA, Villegas-Mercado CE, López-Camarillo C. Bermúdez M, et al. Cancers (Basel). 2024 Aug 10;16(16):2814. doi: 10.3390/cancers16162814. Cancers (Basel). 2024. PMID: 39199587 Free PMC article. Review. - Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.
Zhuang T, Wang S, Yu X, He X, Guo H, Ou C. Zhuang T, et al. Biomark Res. 2024 Aug 26;12(1):88. doi: 10.1186/s40364-024-00639-0. Biomark Res. 2024. PMID: 39183323 Free PMC article. Review. - Hypoxia-Driven Changes in Tumor Microenvironment: Insights into Exosome-Mediated Cell Interactions.
Wang C, Xu S, Yang X. Wang C, et al. Int J Nanomedicine. 2024 Aug 12;19:8211-8236. doi: 10.2147/IJN.S479533. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39157736 Free PMC article. Review. - Changes of circulating tumor cells expressing CD90 and EpCAM in early-phase of atezolizumab and bevacizumab for hepatocellular carcinoma.
Nosaka T, Murata Y, Akazawa Y, Takahashi K, Naito T, Matsuda H, Ohtani M, Nakamoto Y. Nosaka T, et al. Heliyon. 2024 Jul 10;10(14):e34441. doi: 10.1016/j.heliyon.2024.e34441. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39108869 Free PMC article.
References
- Recamier JC. Recherches sur la Traitment du Cancer sur la Compression Methodique Simple ou Combinee et sure l'Histoire Generale de la Meme Maladie. 2 ed. 1829.
- Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3:453–8. - PubMed
- Dorland WA. Dorland's Illustrated Medical Dictionary. 24 ed. Saunders Co.; Philadelphia: 1965.
- Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? Cell Cycle. 2009;8:505–6. - PubMed
- van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 CA016672/CA/NCI NIH HHS/United States
- CA16672/CA/NCI NIH HHS/United States
- CA036727/CA/NCI NIH HHS/United States
- U54 CA143837/CA/NCI NIH HHS/United States
- P30 CA036727/CA/NCI NIH HHS/United States
- 1U54CA143837/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous